Leerink Raises Price Target#
Leerink Partners has increased its price target for Intellia Therapeutics (NASDAQ: NTLA) from $29 to $35 while keeping an Outperform rating on the stock. This adjustment comes after the company released positive results from its recent clinical trial for a treatment called lonvoguran ziclumeran, or lonvo-z.
Positive Trial Results#
The firm has raised its probability of success for lonvo-z to 90% from 75%. This change reflects strong efficacy and safety data from the trial, as well as the initiation of a rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA). The trial results showed an 87% reduction in attacks for patients with hereditary angioedema compared to a placebo over six months.
Stock Performance and Market Reaction#
Despite the positive news, Intellia's stock has seen a muted reaction, gaining only mid-single-digit percentages while the broader biotech index (XBI) rose by 1%. Investors are weighing the positive trial results against concerns about the company's financial health and the lack of immediate catalysts. Over the past week, the stock has declined by 10%, although it remains up 52% year-to-date and 64% over the past year.
Upcoming Presentation#
Intellia is set to present detailed data from the trial at the 2026 European Academy of Allergy and Clinical Immunology Congress in Istanbul from June 12-15. This presentation will include various analyses and longer follow-up data, which Leerink believes will further distinguish lonvo-z from other treatment options that require chronic dosing. Analysts from TD Cowen and BofA Securities have also noted the promising trial results, with BofA raising its price target for Intellia from $19 to $20 while maintaining a Neutral rating.